Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > 3.7 million
View:
Post by prophetoffactz on Jul 30, 2024 9:04am

3.7 million

Stockhouse has update the AEZS shares outstanding to 3.7 million. That likely includes the warrants that were issued to AEZS holders immediately before the merger closed.

That's a C$28 million market cap at C$7.6.

$28 million market cap would be C$.36 per CZO before the merger. 

H.C. Wainwright had a C$100 million market cap target for AEZS before the merger and that was set before a big rally in biotech. 

C$100 million market cap with 3.7 million shares is C$27 per AEZS shares and that ignores the merger of equals potentially doubling the value and that H.C. Wainwright's target was set before a huge surge in biotech shares.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities